Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) t...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 2022-04, Vol.28 (4), p.838-843 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 843 |
|---|---|
| container_issue | 4 |
| container_start_page | 838 |
| container_title | Nature medicine |
| container_volume | 28 |
| creator | Cerqueira-Silva, Thiago Katikireddi, Srinivasa Vittal de Araujo Oliveira, Vinicius Flores-Ortiz, Renzo Júnior, Juracy Bertoldo Paixão, Enny S. Robertson, Chris Penna, Gerson O. Werneck, Guilherme L. Barreto, Maurício L. Pearce, Neil Sheikh, Aziz Barral-Netto, Manoel Boaventura, Viviane S. |
| description | There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.
A test-negative case–control analysis of data from Brazil shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the BNT162b2 vaccine. |
| doi_str_mv | 10.1038/s41591-022-01701-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9018414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627479970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-aea80cce4071d0696b39a41330c116f4ef170663b3d0a07b8aee298990d94bd3</originalsourceid><addsrcrecordid>eNp9kU9vEzEQxS0EIiXwBTiglbj0sjBje73rCxKNaIsUwSVC3CyvdzbZaGMHe9OKfvoaUsKfAyd7NL95M0-PsZcIbxBE8zZJrDSWwHkJWAOWt4_YGVZSlbn6-jj_oW7KRldqxp6ltAUAAZV-ymaiQgkS1Bm7-mKdGzwV1PfkpuGGPKVUhL7Y0EQxjGEdDqlYhBi8zWyxH3N58WmFire8GHxxEe3dMD5nT3o7Jnrx8M7Z6vLDanFdLj9ffVy8X5ZO1nIqLdkGnCMJNXagtGqFthKFAIeoekl9Pl0p0YoOLNRtY4m4brSGTsu2E3P27ii7P7Q76hz5KdrR7OOws_G7CXYwf3f8sDHrcGM0YCNRZoHzB4EYvh0oTWY3JEfjaD1lo4YrXsta6xoy-vofdBsO0Wd3maq4RC44zxQ_Ui6GlCL1p2MQzI-YzDEmk2MyP2Myt3no1Z82TiO_csmAOAIpt_ya4u_d_5G9ByxunXU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2652412322</pqid></control><display><type>article</type><title>Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil</title><source>MEDLINE</source><source>Nature</source><source>Springer Nature - Complete Springer Journals</source><creator>Cerqueira-Silva, Thiago ; Katikireddi, Srinivasa Vittal ; de Araujo Oliveira, Vinicius ; Flores-Ortiz, Renzo ; Júnior, Juracy Bertoldo ; Paixão, Enny S. ; Robertson, Chris ; Penna, Gerson O. ; Werneck, Guilherme L. ; Barreto, Maurício L. ; Pearce, Neil ; Sheikh, Aziz ; Barral-Netto, Manoel ; Boaventura, Viviane S.</creator><creatorcontrib>Cerqueira-Silva, Thiago ; Katikireddi, Srinivasa Vittal ; de Araujo Oliveira, Vinicius ; Flores-Ortiz, Renzo ; Júnior, Juracy Bertoldo ; Paixão, Enny S. ; Robertson, Chris ; Penna, Gerson O. ; Werneck, Guilherme L. ; Barreto, Maurício L. ; Pearce, Neil ; Sheikh, Aziz ; Barral-Netto, Manoel ; Boaventura, Viviane S.</creatorcontrib><description>There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.
A test-negative case–control analysis of data from Brazil shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the BNT162b2 vaccine.</description><identifier>ISSN: 1078-8956</identifier><identifier>ISSN: 1546-170X</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/s41591-022-01701-w</identifier><identifier>PMID: 35140406</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>692/308/174 ; 692/308/409 ; Aged ; Aged, 80 and over ; Biomedical and Life Sciences ; Biomedicine ; BNT162 Vaccine ; Brazil - epidemiology ; Cancer Research ; Confidence intervals ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Humans ; Infections ; Infectious Diseases ; Metabolic Diseases ; Molecular Medicine ; Neurosciences ; Respiratory diseases ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine Efficacy ; Vaccines ; Viral diseases</subject><ispartof>Nature medicine, 2022-04, Vol.28 (4), p.838-843</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-aea80cce4071d0696b39a41330c116f4ef170663b3d0a07b8aee298990d94bd3</citedby><cites>FETCH-LOGICAL-c474t-aea80cce4071d0696b39a41330c116f4ef170663b3d0a07b8aee298990d94bd3</cites><orcidid>0000-0001-7022-3056 ; 0000-0003-4534-2509 ; 0000-0003-1169-1436 ; 0000-0002-9938-7852 ; 0000-0002-4797-908X ; 0000-0001-7858-9650 ; 0000-0001-8967-536X ; 0000-0001-6593-9092 ; 0000-0001-7639-2627 ; 0000-0002-7241-6844</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41591-022-01701-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41591-022-01701-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35140406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cerqueira-Silva, Thiago</creatorcontrib><creatorcontrib>Katikireddi, Srinivasa Vittal</creatorcontrib><creatorcontrib>de Araujo Oliveira, Vinicius</creatorcontrib><creatorcontrib>Flores-Ortiz, Renzo</creatorcontrib><creatorcontrib>Júnior, Juracy Bertoldo</creatorcontrib><creatorcontrib>Paixão, Enny S.</creatorcontrib><creatorcontrib>Robertson, Chris</creatorcontrib><creatorcontrib>Penna, Gerson O.</creatorcontrib><creatorcontrib>Werneck, Guilherme L.</creatorcontrib><creatorcontrib>Barreto, Maurício L.</creatorcontrib><creatorcontrib>Pearce, Neil</creatorcontrib><creatorcontrib>Sheikh, Aziz</creatorcontrib><creatorcontrib>Barral-Netto, Manoel</creatorcontrib><creatorcontrib>Boaventura, Viviane S.</creatorcontrib><title>Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.
A test-negative case–control analysis of data from Brazil shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the BNT162b2 vaccine.</description><subject>692/308/174</subject><subject>692/308/409</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>BNT162 Vaccine</subject><subject>Brazil - epidemiology</subject><subject>Cancer Research</subject><subject>Confidence intervals</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>Metabolic Diseases</subject><subject>Molecular Medicine</subject><subject>Neurosciences</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine Efficacy</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>1078-8956</issn><issn>1546-170X</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU9vEzEQxS0EIiXwBTiglbj0sjBje73rCxKNaIsUwSVC3CyvdzbZaGMHe9OKfvoaUsKfAyd7NL95M0-PsZcIbxBE8zZJrDSWwHkJWAOWt4_YGVZSlbn6-jj_oW7KRldqxp6ltAUAAZV-ymaiQgkS1Bm7-mKdGzwV1PfkpuGGPKVUhL7Y0EQxjGEdDqlYhBi8zWyxH3N58WmFire8GHxxEe3dMD5nT3o7Jnrx8M7Z6vLDanFdLj9ffVy8X5ZO1nIqLdkGnCMJNXagtGqFthKFAIeoekl9Pl0p0YoOLNRtY4m4brSGTsu2E3P27ii7P7Q76hz5KdrR7OOws_G7CXYwf3f8sDHrcGM0YCNRZoHzB4EYvh0oTWY3JEfjaD1lo4YrXsta6xoy-vofdBsO0Wd3maq4RC44zxQ_Ui6GlCL1p2MQzI-YzDEmk2MyP2Myt3no1Z82TiO_csmAOAIpt_ya4u_d_5G9ByxunXU</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Cerqueira-Silva, Thiago</creator><creator>Katikireddi, Srinivasa Vittal</creator><creator>de Araujo Oliveira, Vinicius</creator><creator>Flores-Ortiz, Renzo</creator><creator>Júnior, Juracy Bertoldo</creator><creator>Paixão, Enny S.</creator><creator>Robertson, Chris</creator><creator>Penna, Gerson O.</creator><creator>Werneck, Guilherme L.</creator><creator>Barreto, Maurício L.</creator><creator>Pearce, Neil</creator><creator>Sheikh, Aziz</creator><creator>Barral-Netto, Manoel</creator><creator>Boaventura, Viviane S.</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7022-3056</orcidid><orcidid>https://orcid.org/0000-0003-4534-2509</orcidid><orcidid>https://orcid.org/0000-0003-1169-1436</orcidid><orcidid>https://orcid.org/0000-0002-9938-7852</orcidid><orcidid>https://orcid.org/0000-0002-4797-908X</orcidid><orcidid>https://orcid.org/0000-0001-7858-9650</orcidid><orcidid>https://orcid.org/0000-0001-8967-536X</orcidid><orcidid>https://orcid.org/0000-0001-6593-9092</orcidid><orcidid>https://orcid.org/0000-0001-7639-2627</orcidid><orcidid>https://orcid.org/0000-0002-7241-6844</orcidid></search><sort><creationdate>20220401</creationdate><title>Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil</title><author>Cerqueira-Silva, Thiago ; Katikireddi, Srinivasa Vittal ; de Araujo Oliveira, Vinicius ; Flores-Ortiz, Renzo ; Júnior, Juracy Bertoldo ; Paixão, Enny S. ; Robertson, Chris ; Penna, Gerson O. ; Werneck, Guilherme L. ; Barreto, Maurício L. ; Pearce, Neil ; Sheikh, Aziz ; Barral-Netto, Manoel ; Boaventura, Viviane S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-aea80cce4071d0696b39a41330c116f4ef170663b3d0a07b8aee298990d94bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>692/308/174</topic><topic>692/308/409</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>BNT162 Vaccine</topic><topic>Brazil - epidemiology</topic><topic>Cancer Research</topic><topic>Confidence intervals</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>Metabolic Diseases</topic><topic>Molecular Medicine</topic><topic>Neurosciences</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine Efficacy</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cerqueira-Silva, Thiago</creatorcontrib><creatorcontrib>Katikireddi, Srinivasa Vittal</creatorcontrib><creatorcontrib>de Araujo Oliveira, Vinicius</creatorcontrib><creatorcontrib>Flores-Ortiz, Renzo</creatorcontrib><creatorcontrib>Júnior, Juracy Bertoldo</creatorcontrib><creatorcontrib>Paixão, Enny S.</creatorcontrib><creatorcontrib>Robertson, Chris</creatorcontrib><creatorcontrib>Penna, Gerson O.</creatorcontrib><creatorcontrib>Werneck, Guilherme L.</creatorcontrib><creatorcontrib>Barreto, Maurício L.</creatorcontrib><creatorcontrib>Pearce, Neil</creatorcontrib><creatorcontrib>Sheikh, Aziz</creatorcontrib><creatorcontrib>Barral-Netto, Manoel</creatorcontrib><creatorcontrib>Boaventura, Viviane S.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cerqueira-Silva, Thiago</au><au>Katikireddi, Srinivasa Vittal</au><au>de Araujo Oliveira, Vinicius</au><au>Flores-Ortiz, Renzo</au><au>Júnior, Juracy Bertoldo</au><au>Paixão, Enny S.</au><au>Robertson, Chris</au><au>Penna, Gerson O.</au><au>Werneck, Guilherme L.</au><au>Barreto, Maurício L.</au><au>Pearce, Neil</au><au>Sheikh, Aziz</au><au>Barral-Netto, Manoel</au><au>Boaventura, Viviane S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>28</volume><issue>4</issue><spage>838</spage><epage>843</epage><pages>838-843</pages><issn>1078-8956</issn><issn>1546-170X</issn><eissn>1546-170X</eissn><abstract>There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.
A test-negative case–control analysis of data from Brazil shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the BNT162b2 vaccine.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>35140406</pmid><doi>10.1038/s41591-022-01701-w</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-7022-3056</orcidid><orcidid>https://orcid.org/0000-0003-4534-2509</orcidid><orcidid>https://orcid.org/0000-0003-1169-1436</orcidid><orcidid>https://orcid.org/0000-0002-9938-7852</orcidid><orcidid>https://orcid.org/0000-0002-4797-908X</orcidid><orcidid>https://orcid.org/0000-0001-7858-9650</orcidid><orcidid>https://orcid.org/0000-0001-8967-536X</orcidid><orcidid>https://orcid.org/0000-0001-6593-9092</orcidid><orcidid>https://orcid.org/0000-0001-7639-2627</orcidid><orcidid>https://orcid.org/0000-0002-7241-6844</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 2022-04, Vol.28 (4), p.838-843 |
| issn | 1078-8956 1546-170X 1546-170X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9018414 |
| source | MEDLINE; Nature; Springer Nature - Complete Springer Journals |
| subjects | 692/308/174 692/308/409 Aged Aged, 80 and over Biomedical and Life Sciences Biomedicine BNT162 Vaccine Brazil - epidemiology Cancer Research Confidence intervals Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines Humans Infections Infectious Diseases Metabolic Diseases Molecular Medicine Neurosciences Respiratory diseases SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccine Efficacy Vaccines Viral diseases |
| title | Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T01%3A40%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccine%20effectiveness%20of%20heterologous%20CoronaVac%20plus%20BNT162b2%20in%20Brazil&rft.jtitle=Nature%20medicine&rft.au=Cerqueira-Silva,%20Thiago&rft.date=2022-04-01&rft.volume=28&rft.issue=4&rft.spage=838&rft.epage=843&rft.pages=838-843&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/s41591-022-01701-w&rft_dat=%3Cproquest_pubme%3E2627479970%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2652412322&rft_id=info:pmid/35140406&rfr_iscdi=true |